Events and Medicine Grand Rounds Schedule

1 March Mar

Diabetes Center Conference

Fri Mar 01 2024, 9:00 AM

Speaker: John Newman, MD, PhD
Assistant Professor Buck Institute for Research on Aging

351, Price Center/Block Pavilion

More

If unable to attend in person, below is the zoom information.

Zoom information
https://einsteinmed.zoom.us/j/95425671231
Meeting ID: 954 2567 1231
Phone: 1-646-558-8656

5 March Mar

Omics Club Weekly Workshop

Tue Mar 05 2024, 12:00 PM

Speaker: Dr. Srilakshmi Raj
Ancestry analysis vignette designer: David Yang

Riklis Auditorium

More

For details, please see the following URL: https://einsteinomics.github.io/omics-workshop2024/

5 March Mar

Biochemistry Seminar Series " Proteogenomic approach for understanding novel biology of fusion-kinase driven lymphoma"

Tue Mar 05 2024, 12:00 PM

Speaker: Megan So-Young Lim, M.D., Ph.D.
Attending Pathologist Director, Lymphoma Translational Research Program Director, Multispectral Imaging Lab Joint Member, HOPP Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center

3rd Floor Lecture Hall, Forchheimer

More

Peripheral T cell lymphomas are heterogeneous neoplasms of post thymic T cells with distinct clinical, pathological and genetic characteristics. Poor understanding of mechanisms underlying the pathogenesis of PTCL contributes to suboptimal diagnostic subcategorization and lack of targeted therapies. Our research laboratory leverages large scale mass spectrometry-based proteomic, phosphoproteomic and genomic analyses to identify novel signaling pathways regulated by oncogenic fusion kinases in lymphoma.  Utilizing this strategy, we previously identified the NPM::TYK2 fusion in patients with CD30+ lymphoproliferative disorders, including 15% of primary cutaneous ALK- anaplastic large cell lymphoma. Notably, genetic alterations of TYK2 had not been reported in human cancer Subsequently, recurrent fusions targeting kinase-driven TYK2 have been corroborated and observed in other subtypes of T-cell lymphomas implicating its candidacy as an oncogenic kinase. The unequivocal rigorous scientific authentication as a de facto oncogenic driver in vivo has yet to be demonstrated.   The oncogenicity of NPM1::TYK2 and its effect on T cell differentiation, the molecular mechanisms and signaling pathways through which it drives lymphomagenesis in vivo remain unknown.  In this presentation, the proteogenomic strategy for the discovery of the novel TYK2 fusion and subsequent studies to investigate the oncogenic function of TYK2 fusions in lymphoma will be discussed.

6 March Mar

Pediatrics Grand Rounds "Leveraging the Translational CAR Experience to Enhance Clinical Outcomes”

Wed Mar 06 2024, 8:00 AM

Speaker: Liora Michal Schultz, MD
Clinical Assistant Professor Practices at Stanford Medicine Children's Health Department: Pediatrics - Hematology/Oncology Lucile Packard Children's Hospital Stanford, Palo Alto, CA

Cherkasky Auditorium and via Zoom, Montefiore

More

Pediatric Grand Rounds will be video conferenced (via Zoom) to the following locations:

Einstein campus –Price Center Rm 151; Wakefield- 4th Fl Conf. Rm; New Rochelle – NICU Work Room 4th Fl; CFCC Conf. Rm

Join Zoom:  https://montefiore.zoom.us/j/748563750   Tel US: +1 646 558 8656 or +1 669 900 6833

Meeting ID:  748 563 750    Password/Code:  724118       

Albert Einstein College of Medicine of Yeshiva University designates this live educational activity for a maximum of one 1 AMA PRA Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.